Company profile: CRYOPDP
1.1 - Company Overview
Company description
- Provider of innovative temperature-controlled logistics solutions to the clinical research, pharmaceutical, and cell and gene therapy markets, ensuring safe transport of temperature-sensitive life science and healthcare cargo. Offers pick & pack services, dry ice and liquid nitrogen supply with related cryogenic equipment, and temperature-controlled packaging and passive insulated box solutions.
Products and services
- Packaging Solutions: Modular temperature-controlled packaging systems utilizing dry ice, liquid nitrogen, gel packs, and phase‑change materials to maintain precise temperatures for medical shipments during transport
- Passive Solutions: Industrial‑grade insulated boxes enabling deep frozen, frozen, refrigerated, and controlled‑ambient transport of biological samples and pharmaceuticals, ensuring extended temperature control without active refrigeration
- Temperature-Controlled Logistics Solutions: Cold-chain engineered service ensuring safe, secure transport of temperature‑sensitive life science cargo, including biological samples and pharmaceutical drugs, supporting clinical research, pharmaceutical, and cell and gene therapy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CRYOPDP
Curapath
HQ: Spain
Website
- Description: Provider of polymer and lipid-based drug delivery systems—including polymer and lipid nanoparticles—offering custom design through preclinical development to commercial-scale pharmaceutical manufacturing, plus drug conjugation and cross-linking services to enhance stability, reduce toxicity, and improve bioactivity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Curapath company profile →
Eximia Research
HQ: United States
Website
- Description: Provider of multi-therapeutic clinical research site network services for biotech companies, conducting Phase I–IV clinical trials across therapeutic and diagnostic indications. Offers patient recruitment and engagement (including underrepresented populations), feasibility studies with investigator feedback, rapid site start-up and feasibility, regulatory and start-up support (contract and budget management), and quality assurance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eximia Research company profile →
Clinilabs
HQ: United States
Website
- Description: Provider of clinical drug development services specializing in CNS medications, from first-in-human to Phase 3 trials. Offers global site selection via a network in 42 countries, decentralized trials using telemedicine, electronic tools, remote assessment and wearables, corelab data services to centralize and improve data accuracy, and centralized PSG and EEG capture and analysis for clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clinilabs company profile →
Seqens
HQ: France
Website
- Description: Provider of integrated pharmaceutical synthesis and specialty ingredients, delivering market responsiveness and tailor-made solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seqens company profile →
Primrose Bio
HQ: United States
Website
- Description: Provider of biotechnology solutions for discovery, development, and manufacturing of new molecules, including Pfenex Expression Technology for high-yield production of complex proteins, Prima RNApols to enhance mRNA yield and quality, PeliCRM197 carrier protein for conjugate vaccines, the Function Generator for novel gene creation, and EOS for enzymatic DNA/RNA oligonucleotide synthesis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Primrose Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CRYOPDP
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CRYOPDP
2.2 - Growth funds investing in similar companies to CRYOPDP
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CRYOPDP
4.2 - Public trading comparable groups for CRYOPDP
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →